CMP (Comprehensive Metabolic Panel) Longevity-Medicine Target Ranges

The comprehensive metabolic panel, usually ordered as "CMP" or "chem-14," is a 14-marker blood test covering glucose, kidney function (BUN, creatinine, eGFR, BUN/creatinine ratio), liver function (ALT, AST, alkaline phosphatase, bilirubin), and electrolyte/protein status (sodium, potassium, chloride, CO2, calcium, total protein, albumin). It is a superset of the basic metabolic panel (BMP), which covers the same electrolyte and kidney markers but omits the liver and protein tests.

The direct answer

A standard CMP is built to flag disease: values are marked abnormal only when they fall outside roughly the 95th percentile of a general lab population, a population that itself includes many people with undiagnosed prediabetes or fatty liver. Longevity-oriented clinicians instead look at where a value sits within the normal range and whether it is drifting toward the edge of that range across repeated draws over years. The evidence for this approach is strongest for glucose, eGFR trajectory, ALT, and albumin, where multiple observational cohorts have linked "normal but not optimal" values to higher long-term risk; it is weaker and more provisional for several of the electrolyte and calcium targets discussed below. None of the narrower windows in this article are diagnostic thresholds, and none should be used to self-diagnose or self-treat.

Why a "normal" CMP result is not the same as an optimal one

Laboratory reference intervals are statistical, not physiological: they are usually built from the central 95% of a tested population, which is not a population selected for excellent metabolic health. A result at the edge of "normal" is still flagged normal even if longitudinal data associate it with worse outcomes over one or two decades. This is the rationale for the longevity-medicine practice of narrowing target windows and, more importantly, of tracking direction of change rather than a single pass/fail read.

Evidence boundary. What is reasonably well established: fasting glucose above the mid-80s mg/dL and eGFR trajectories that decline over years, even while staying above 60, are associated with higher future risk in multiple population studies, and treating trajectory (not just a single threshold) as informative is consistent with guideline language on CKD progression. What is plausible but not settled: many of the exact numeric cutoffs used in longevity practice (for example, single-digit mg/dL glucose bands, specific sodium or potassium decimal targets) come from individual cohort analyses that have not been independently replicated into a consensus guideline. What is not established: that intervening to keep every marker inside the "optimal" band, rather than the conventional normal band, changes hard outcomes such as mortality or cardiovascular events. Readers should treat the narrower targets in this article as a framework for conversation with a clinician, not as a diagnostic standard.

Glucose: the most actionable single number on the panel

The American Diabetes Association classifies fasting plasma glucose as normal below 100 mg/dL, impaired fasting glucose (prediabetes) at 100-125 mg/dL, and diabetes at 126 mg/dL or above on repeated testing; these thresholds are well established and widely used in primary care (see ADA guidance at diabetes.org).

Longevity-medicine practice narrows the "optimal" window further, commonly to roughly 70-85 mg/dL fasting, based on observational cohort work (including the Framingham Offspring Study) suggesting that fasting glucose in the high-normal range predicts a meaningfully higher rate of future diabetes conversion than glucose in the low-normal range. The exact magnitude of that risk difference varies by cohort and should not be quoted as a precise multiplier without checking the specific paper; readers or clinicians who want the exact hazard ratio should verify it against the primary Framingham publication rather than relying on secondary citations.

The CMP does not include insulin. A fasting glucose of 84 mg/dL with a fasting insulin of 18 µIU/mL implies a very different metabolic picture than the same glucose with an insulin of 4 µIU/mL. Adding a fasting insulin test allows calculation of HOMA-IR (glucose in mg/dL × insulin in µIU/mL ÷ 405); lower HOMA-IR values generally reflect better insulin sensitivity, though the exact HOMA-IR cutoff that predicts future diabetes differs across published cohorts and should be interpreted by a clinician rather than compared against a single number found online.

Kidney function: eGFR, creatinine, and BUN

eGFR is calculated from serum creatinine, age, and sex using a CKD-EPI equation; the current recommended version dates to 2021 and is used in KDIGO guidance (see kdigo.org). Standard CKD staging treats eGFR values from roughly 90 to 120 as uniformly normal and does not distinguish a stable eGFR of 95 from a declining one.

Longevity practice treats an eGFR trajectory as more informative than a single value. Guideline language on CKD progression supports this general principle: a confirmed year-over-year decline is treated as clinically meaningful even when the most recent value is still above the stage-defining threshold, though the exact magnitude that counts as "rapid progression" should be confirmed against the current KDIGO guideline text rather than assumed from a secondary summary.

Serum creatinine is a byproduct of muscle creatine metabolism. A well-muscled person can run a creatinine of 1.2-1.4 mg/dL with no kidney dysfunction at all, which is why creatinine-only interpretation without body composition context, or without a cystatin C cross-check in ambiguous cases, can be misleading.

BUN rises with high protein intake, dehydration, gastrointestinal bleeding, or reduced kidney clearance, so an isolated BUN value needs context. The BUN/creatinine ratio helps: a ratio above roughly 20:1 suggests a pre-renal cause such as dehydration or a high protein load; a ratio below roughly 10:1 can point toward reduced urea synthesis from liver disease or very low protein intake. These ratio bands are general clinical heuristics, not precise diagnostic cutoffs.

Liver enzymes: ALT, AST, ALP, and bilirubin

ALT is the most liver-specific enzyme on the panel. Conventional upper limits of normal for ALT (commonly around 40 U/L for men and 32 U/L for women on many lab reports) were set using reference populations that likely included people with undiagnosed fatty liver disease. Some published analyses using stricter "metabolically healthy" reference populations have proposed lower upper limits, and longevity-oriented clinicians often use ALT above roughly 25 U/L in men or 19 U/L in women, even within a lab's printed normal range, as a prompt to look further for early hepatic steatosis. Nonalcoholic fatty liver disease is common in the general population, which is part of why a "normal" ALT does not fully rule it out; the exact global prevalence figure varies by study population and year and should be checked against a current source rather than treated as fixed.

The AST/ALT ratio adds context: a ratio above roughly 2:1 raises concern for alcohol-related liver injury or more advanced fibrosis, while a ratio at or below 1.0 with both enzymes mildly elevated is a more typical fatty-liver pattern. Alkaline phosphatase elevation can reflect bone turnover, cholestatic liver disease, or thyroid dysfunction, and is best interpreted alongside gamma-glutamyl transferase (GGT), which is not part of the standard CMP. Total bilirubin in the upper-normal range has been linked to lower cardiovascular event rates in some observational data, but this association has not been shown to be causal, and bilirubin is also affected by benign conditions such as Gilbert syndrome.

Electrolytes: sodium, potassium, chloride, and bicarbonate

Standard sodium reference ranges (commonly 135-145 mEq/L) are wide. Some population-based analyses have associated sodium in the high-normal range with markers of accelerated biological aging, but this line of evidence is newer and less replicated than the glucose or eGFR findings above; readers should treat any specific odds ratio quoted for this association as needing verification against the original paper rather than as an established fact.

Potassium sits at the intersection of diet, kidney function, and cardiac rhythm. Low-normal potassium has been associated with higher blood pressure and a higher rate of new atrial fibrillation in large cohort studies; a diet rich in fruits, vegetables, and legumes is the standard first-line way to support potassium in the upper part of the normal range, alongside attention to kidney function and any potassium-affecting medications.

Serum bicarbonate (CO2) reflects the metabolic side of acid-base balance. Bicarbonate persistently at the low end of normal has been associated in some studies with faster kidney function decline and greater bone and muscle catabolism over time in patients with existing CKD; whether this applies to metabolically healthy adults with no kidney disease is less clear and should not be assumed.

Albumin and total protein

Albumin is one of the more consistently studied longevity-relevant markers on the CMP. Multiple observational cohorts in older adults have linked albumin toward the low end of the normal range (below roughly 4.0 g/dL) with higher all-cause mortality over follow-up periods of a decade or more, even though such values are not flagged abnormal by standard lab criteria. Albumin reflects both hepatic synthetic function and nutritional protein status, so a low-normal value in an otherwise healthy-appearing person can be an early signal worth discussing with a clinician rather than dismissing.

Total protein reflects both albumin and globulin fractions. An elevated total protein paired with low-normal albumin implies elevated globulins, which can reflect chronic inflammation, a chronic infection, or, less commonly, a plasma cell disorder, and generally warrants follow-up rather than reassurance.

The CMP Drift Decision Framework

Most of the genuine decision-making value in a longevity-oriented CMP comes from three questions asked together, not from any single number. This framework is a way to organize that conversation with a clinician; it is not a substitute for clinical judgment and does not replace guideline-based diagnostic thresholds.

Step 1: Where does the value sit relative to three zones?

• Conventional Normal: inside the lab's printed reference range.
• Watch Zone: inside the lab's normal range but outside the narrower longevity-practice target discussed above.
• Target Zone: inside the narrower longevity-practice target.

A single Watch Zone value, by itself, is not a diagnosis and does not require urgent action.

Step 2: Is there directional drift across three or more annual draws? A value moving consistently toward the edge of its range across repeated draws (for example, fasting glucose rising from 81 to 84 to 88 to 93 mg/dL over four years) is a materially different signal than a single value in the Watch Zone. Directional drift across multiple years, confirmed with standardized draw conditions, is the strongest single piece of evidence this article can support for "act now versus keep monitoring."

Step 3: Does the Watch Zone value corroborate with a marker from a different cluster? A single mildly elevated ALT means less than an ALT elevation that coincides with a fasting glucose trending upward and a rising waist circumference or BMI. Cross-cluster corroboration (glucose plus liver plus a body-composition or blood-pressure signal) raises the practical weight of an otherwise borderline value; an isolated Watch Zone value in one cluster, with everything else stable, more often reflects normal biological variability, recent illness, dehydration, or exercise timing than a real trend.

Exceptions that override the framework:

• Muscular individuals with elevated creatinine but normal cystatin C and no other kidney signal should not be treated as having reduced kidney function.
• New medications (statins, ACE inhibitors/ARBs, chronic NSAIDs, PPIs) can shift ALT, AST, creatinine, potassium, or eGFR in predictable directions; a change coinciding with a new prescription should prompt a medication review before a disease workup.
• Acute illness, dehydration, high-intensity exercise in the prior 48 hours, alcohol within 72 hours, and non-fasting draws can all move CMP values enough to create false drift; a single outlier value after a known confounder should be repeated under standardized conditions before it is trusted.
• Any single value that crosses an actual diagnostic threshold (glucose ≥126 mg/dL, eGFR persistently below 60, calcium clearly above the lab's upper limit) should prompt clinical follow-up on its own, regardless of trend, and is outside the scope of this "optimal range" discussion.

Next step if a value stays in the Watch Zone with confirmed drift: bring the trended results, current medication list, and any relevant symptoms to a clinician visit rather than attempting to interpret or treat the pattern alone. Longevity-practice targets are a prompt for a more detailed conversation, not a treatment protocol.

How to reduce noise between draws

Standardizing conditions makes trending meaningful: a 10-12 hour fast, no high-intensity exercise the evening before, adequate hydration, and documentation of any medication changes, recent illness, or alcohol intake. Without this standardization, apparent "drift" across visits can simply be draw-condition noise rather than a real physiological trend.

Medications that can shift CMP values

Several common medications move CMP markers in predictable ways that can be mistaken for new disease:

• Statins can raise ALT and AST in a minority of patients, occasionally to a degree that meets standard criteria for clinically significant hepatotoxicity, which is one reason liver enzymes are checked periodically during statin therapy.
• Metformin lowers glucose as intended and can modestly raise creatinine by competing for renal tubular secretion without reflecting true kidney injury.
• ACE inhibitors and ARBs commonly raise creatinine modestly and can raise potassium, an effect that is more pronounced when baseline kidney function is already reduced.
• Chronic NSAID use can reduce eGFR by altering renal blood flow, an effect that is usually reversible after stopping the drug.
• Long-term proton pump inhibitor use has been associated with declining eGFR and low magnesium in observational data, though magnesium is not part of the standard CMP.

A current medication list should be reviewed at every CMP visit alongside the results themselves.

Reference table: conventional range versus commonly used longevity-practice target

These "practice target" numbers are drawn from a mix of cohort studies of varying size and quality, and none of them are FDA labels, single-society consensus guidelines, or diagnostic thresholds. Exact figures vary somewhat by lab, assay, and population, and should be confirmed with a clinician rather than applied mechanically.

Guideline context

Diabetes guidance from the American Diabetes Association emphasizes interpreting glucose and A1C in the context of the whole clinical picture rather than a single absolute number in isolation. CKD guidance from KDIGO similarly treats a confirmed decline in eGFR over time as clinically meaningful even before a person crosses into a lower CKD stage. Together, these two general guideline principles, trend-aware rather than threshold-only interpretation, support the broad approach used in this article, though readers should consult the current published guideline text for exact wording and thresholds rather than relying on this summary.